Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martina Bonechi

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Breast Care (Basel, Switzerland)|December 14, 2017
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of ResponseCristina Guarducci, Martina Bonechi, Giulia Boccalini, et al.
Cancer Treatment Reviews|December 28, 2020
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancerIlenia Migliaccio, Martina Bonechi, Amelia McCartney, et al.
Oncotarget|September 17, 2016
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancerLuca Malorni, Silvano Piazza, Yari Ciani, et al.
NPJ Breast Cancer|July 30, 2025
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell linesIlenia Migliaccio, Martina Bonechi, Dario Romagnoli, et al.
BMC Genomics|December 26, 2018
ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq dataDario Romagnoli, Giulia Boccalini, Martina Bonechi, et al.
Frontiers in Oncology|August 10, 2019
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical PracticeAmelia McCartney, Ilenia Migliaccio, Martina Bonechi, et al.
Breast Cancer Research and Treatment|March 23, 2018
A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patientsEmanuela Risi, Andrea Grilli, Ilenia Migliaccio, et al.
Cells|March 14, 2020
Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib<sup>.</sup>Nicla Lorito, Marina Bacci, Alfredo Smiriglia, et al.
Oncotarget|April 18, 2018
Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapyMartina Bonechi, Francesca Galardi, Chiara Biagioni, et al.
NPJ Breast Cancer|December 5, 2018
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancerCristina Guarducci, Martina Bonechi, Matteo Benelli, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Breast Care (Basel, Switzerland)|December 14, 2017
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of ResponseCristina Guarducci, Martina Bonechi, Giulia Boccalini, et al.
Cancer Treatment Reviews|December 28, 2020
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancerIlenia Migliaccio, Martina Bonechi, Amelia McCartney, et al.
Oncotarget|September 17, 2016
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancerLuca Malorni, Silvano Piazza, Yari Ciani, et al.
NPJ Breast Cancer|July 30, 2025
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell linesIlenia Migliaccio, Martina Bonechi, Dario Romagnoli, et al.
BMC Genomics|December 26, 2018
ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq dataDario Romagnoli, Giulia Boccalini, Martina Bonechi, et al.
Frontiers in Oncology|August 10, 2019
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical PracticeAmelia McCartney, Ilenia Migliaccio, Martina Bonechi, et al.
Breast Cancer Research and Treatment|March 23, 2018
A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patientsEmanuela Risi, Andrea Grilli, Ilenia Migliaccio, et al.
Cells|March 14, 2020
Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib<sup>.</sup>Nicla Lorito, Marina Bacci, Alfredo Smiriglia, et al.
Oncotarget|April 18, 2018
Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapyMartina Bonechi, Francesca Galardi, Chiara Biagioni, et al.
NPJ Breast Cancer|December 5, 2018
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancerCristina Guarducci, Martina Bonechi, Matteo Benelli, et al.
Pageof 2